1ORNBV Orion Corporation

ORION CORPORATION MANAGERS’ TRANSACTIONS 6 MAY 2024 at 12.00 EEST        

Orion Corporation: Managers’ transactions – Karen Lykke Sørensen

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Karen Lykke SorensenPosition: Member of the Board/Deputy memberIssuer: Orion OyjLEI: 74370029VAHCXDR7B745Notification type: INITIAL NOTIFICATIONReference number: 61639/4/4

____________________________________________Transaction date: 2024-05-03Outside a trading venueInstrument type: SHAREISIN: FI0009014377Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE

Transaction details(1): Volume: 556 Unit price: 0 EUR

Aggregated transactions (1): Volume: 556 Volume weighted average price: 0 EUR

Orion Corporation

Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp://www.orion.fi/enhttp://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

Grafico Azioni Orion (BIT:1ORNBV)
Storico
Da Feb 2025 a Mar 2025

Grafico Azioni Orion (BIT:1ORNBV)
Storico
Da Mar 2024 a Mar 2025